Tagrix 80 mg (Osimertinib)- 30 Tablets

Introduction Of Tagrix 80 Mg

Tagrix 80 mg is a powerful oral medication used in the treatment of non-small cell lung cancer (NSCLC). This targeted therapy contains Osimertinib, a third-generation EGFR-TKI, specifically designed to fight advanced and metastatic lung cancers caused by EGFR mutations. Manufactured by Beacon Pharmaceuticals Ltd., Tagrix has become a trusted choice for patients and doctors worldwide seeking an affordable Osimertinib alternative to expensive brand-name drugs like Tagrisso.

Pharmaceutical Formulation of Tagrix 80 mg

Tagrix 80 mg tablets are film-coated oral medications specifically formulated for targeted cancer therapy. Each tablet contains Osimertinib mesylate, equivalent to 80 mg of Osimertinib, which is the active ingredient responsible for blocking the activity of mutant EGFR proteins in non-small cell lung cancer (NSCLC).

This Tagrix oral formulation ensures maximum bioavailability when taken once daily. The tablet is designed for easy swallowing and stable absorption, whether taken with or without food. The pharmaceutical-grade excipients used in Tagrix help maintain tablet integrity, improve shelf life, and ensure consistent drug release.

Key Formulation Details:

• Active Ingredient: Osimertinib mesylate (equivalent to 80 mg Osimertinib)
• Form: Film-coated tablet
• Administration Route: Oral (Tagrix oral tablet)
• Strength: 80 mg per tablet
• Color & Shape: Yellow, oval-shaped tablet for easy identification and intake

Composition (Excipients may include):

• Microcrystalline Cellulose
• Lactose Monohydrate
• Croscarmellose Sodium
• Colloidal Silicon Dioxide
• Magnesium Stearate
• Polyvinyl Alcohol
• Titanium Dioxide
• Macrogol
• Talc
• Iron Oxide Yellow

These pharmaceutical excipients are carefully selected to ensure proper tablet stability, disintegration, and consistent absorption of the Tagrix oral dose. The film coating enhances tablet appearance and improves swallowing comfort, which is crucial for long-term cancer therapy compliance.

This composition ensures that each Tagrix 80 mg tablet delivers high-quality Osimertinib in a safe and effective formulation for patients with EGFR-mutated non-small cell lung cancer.

Indications: When is Tagrix 80 Mg Prescribed?

Tagrix 80 mg is primarily prescribed for the treatment of non-small cell lung cancer (NSCLC) in patients with specific genetic mutations. It is a targeted therapy designed to improve survival and slow disease progression in advanced cases.

Tagrix 80 Mg is commonly prescribed for:

• First-line treatment of EGFR mutation-positive NSCLC 
• Treatment of NSCLC with acquired T790M resistance mutation 
• Advanced or metastatic non-small cell lung cancer 
• Maintenance therapy after disease progression

Tagrix 80 mg isn’t just a treatment, it’s precision medicine for those who need it most. Its targeted action offers new hope where traditional therapies fall short.

Why doctors choose Tagrix:

Here’s why many doctors recommend it for eligible NSCLC patients:

• Targets key EGFR mutations effectively in NSCLC.
• Improves patient survival and controls disease progression.
• Has fewer side effects and is well-tolerated.
• Affordable generic alternative to Tagrisso with the same Osimertinib.
• Made by trusted manufacturer Beacon Pharmaceuticals Ltd.

How Does Tagrix Work? — Mechanism of Action

Tagrix 80 mg contains Osimertinib, a targeted therapy designed to block abnormal signals in cancer cells. It specifically inhibits mutated forms of the epidermal growth factor receptor (EGFR), including the common activating mutations and the resistant T790M mutation seen in non-small cell lung cancer (NSCLC).

By binding irreversibly to these mutated EGFR proteins, Tagrix prevents the cancer cells from receiving growth signals, which slows down or stops tumor growth and spread. This mechanism of action makes Tagrix highly effective in patients whose lung cancer is driven by EGFR mutations, offering improved progression-free survival compared to traditional chemotherapy.

Because it selectively targets cancer cells while sparing healthy ones, Tagrix oral tablets tend to have fewer side effects, improving patient tolerability during treatment.

This targeted mechanism helps:

• Slow down tumor growth by blocking mutated EGFR proteins.
• Overcome resistance to previous EGFR treatments, like T790M mutation.
• Reduce side effects by targeting cancer cells while sparing healthy ones.

Dosage & Administration: How to Take Tagrix Safely

Tagrix 80 mg (Osimertinib) is an oral medication prescribed to treat non-small cell lung cancer (NSCLC) caused by EGFR mutations. To ensure the most effective and safe treatment, it’s essential to follow the dosage instructions provided by your doctor.

Recommended Dosage of Tagrix 80 mg

• Standard Dose: Take one Tagrix 80 mg tablet once daily.
• With or Without Food: Tagrix can be taken with or without food, based on your preference.
• Swallow Whole: Swallow the tablet whole with a glass of water. Do not crush, chew, or split the tablet.
• Missed Dose: If you miss a dose, take it as soon as you remember, unless it’s almost time for your next dose. Do not take two doses at once to make up for a missed dose.

Tagrix Dose Adjustment

• Dose Reductions: In case of severe side effects, your doctor may recommend a dose reduction.
• Treatment Duration: The duration of treatment with Tagrix 80 mg depends on how well you respond to the medication and the progression of your cancer. It is typically continued until disease progression or intolerable side effects occur.

Important Safety Tips

• Do not stop or change the dose without consulting your doctor, even if symptoms improve.
• Regular Monitoring: Your doctor will likely conduct regular tests to monitor your response to Tagrix and adjust the dosage if necessary.
• Avoid Grapefruit: Do not consume grapefruit or grapefruit juice during treatment with Tagrix, as it may interfere with the medication’s absorption.
• Maintain open communication with your healthcare team and report any unusual symptoms immediately.

Taking Tagrix 80 mg as prescribed can minimize potential risks and ensure maximum benefit from treatment.

Tagrix FDA Approval & Regulatory Status

Tagrix is a generic formulation of Osimertinib, which is FDA approved and marketed globally under the brand name Tagrisso. The Tagrix brand offers the same quality at a more affordable price.

Tagrix 80 mg (Osimertinib) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of non-small cell lung cancer (NSCLC) since 2015. Below is the timeline of its regulatory status:

• 2015: The FDA approved Osimertinib under the brand name Tagrisso (Tagrix is the generic version) for the treatment of EGFR T790M mutation-positive metastatic NSCLC.
• 2017: The FDA expanded its approval to include the first-line treatment of EGFR mutation-positive NSCLC based on positive clinical trial results.
• 2020: Tagrix was further approved for adjuvant treatment in early-stage NSCLC following surgery or chemotherapy in certain patients with EGFR mutations.
• Present Day: Tagrix continues to be a first-line and maintenance therapy for patients with EGFR-mutant NSCLC in the U.S. and other global markets.

Tagrix 80 mg is a high-quality generic alternative manufactured by Beacon Pharmaceuticals Ltd., containing the trusted active ingredient Osimertinib. This generic medicine meets all FDA guidelines and international quality standards, offering an affordable and reliable option for patients worldwide.

Clinical Benefits of Tagrix 80 mg

Tagrix 80 mg (Osimertinib) offers several important clinical benefits for patients with non-small cell lung cancer (NSCLC), making it a preferred choice among oncologists and patients alike:

• Effective Targeting of EGFR Mutations
  Tagrix selectively inhibits both common activating EGFR mutations and the resistant T790M mutation, leading to better control of tumor growth.
• Improved Progression-Free Survival
  Patients treated with Tagrix experience longer periods without disease progression compared to earlier-generation EGFR inhibitors.
• Oral Administration for Convenience
  As a once-daily oral tablet, Tagrix 80 mg offers ease of use and better quality of life, avoiding the need for intravenous chemotherapy.
• Reduced Side Effects Compared to Chemotherapy
  Tagrix is generally better tolerated with fewer severe adverse effects, supporting longer-term treatment adherence.
• Crosses the Blood-Brain Barrier
  Unlike many other EGFR inhibitors, Tagrix effectively penetrates the brain, helping control and prevent brain metastases.
• FDA-Approved and Globally Recognized
  The medication is FDA-approved and accepted in many countries, providing a trusted treatment option worldwide.
• Affordable Generic Option by Beacon Pharmaceuticals
  Tagrix offers a cost-effective alternative to branded Osimertinib (Tagrisso), improving access to life-saving therapy.

Side Effects of Tagrix 80 Mg

While Tagrix 80 mg (Osimertinib) is effective in treating non-small cell lung cancer, some patients may experience side effects. Knowing these helps you stay informed and seek medical advice promptly if needed.

Common Side Effects

These are usually mild and often improve as your body adjusts:

• Diarrhea
• Rash or dry skin
• Nail changes or infections
• Fatigue or tiredness
• Cough or breathing difficulty
• Nausea or vomiting
• Decreased appetite
• Mouth sores
• Muscle or joint pain

Serious but Less Common Side Effects

Though rare, some side effects may need urgent medical attention:

• Heart rhythm changes (QT prolongation)
• Interstitial lung disease or pneumonitis (inflammation in lungs)
• Severe skin reactions (blistering, peeling)
• Liver enzyme elevations indicating liver damage
• Eye problems, including inflammation or vision changes
• Low blood cell counts (anemia, neutropenia)

Unique Points to Know

• Tagrix may cause lung inflammation, so any new or worsening cough or shortness of breath should be reported immediately.
• Patients with heart conditions should be monitored closely due to potential effects on heart rhythm.
• Regular liver function tests are recommended during treatment to detect early liver issues.
• Some patients may develop severe skin reactions, which require stopping the medication immediately.
• Monitoring blood counts is important to avoid infection risks related to low white blood cells.

What To Do

If you experience chest pain, severe shortness of breath, persistent fever, unusual bruising or bleeding, vision problems, or severe skin reactions, stop taking Tagrix drug and seek emergency medical help right away. 

Tagrix in Pregnancy & Breastfeeding

• Tagrix is not recommended during pregnancy due to potential harm to the unborn baby.
• Women of childbearing age should use effective contraception during and for 6 weeks after treatment.
• Breastfeeding should be avoided while on Tagrix and for at least 2 weeks after the last dose.

Always communicate with your physician for personalized advice in this crucial time.

Warnings and Precautions for Use

• Patients with heart problems, eye disorders, or liver conditions should inform their doctor before starting Tagrix 80 mg.
• Avoid grapefruit or grapefruit juice while on Tagrix.
• In case of overdose, seek immediate medical help. Overdose may increase side effects like QT prolongation or breathing difficulty.

Overdose and Emergency Advice for Tagrix 80 Mg

Tagrix 80 mg (Osimertinib) must be taken exactly as prescribed. Overdose can lead to serious health risks.

What Happens If Overdose Tagrix?

• Severe diarrhea or dehydration
• Breathing problems (pneumonitis)
• Heart rhythm issues (QT prolongation)
• Liver damage
• Blood cell abnormalities
• Extreme fatigue or weakness

Emergency Signs

• Chest pain or irregular heartbeat
• Sudden shortness of breath
• Fainting or confusion
• Severe diarrhea
• Yellowing of skin/eyes
• Unusual bruising or bleeding

What to Do

• Call emergency services or go to the nearest hospital immediately
• Provide details of dose and time taken
• Take the medication packaging, if possible

Prevention Tips

• Never double the dose for a missed one
• Keep Tagrix in its original package
• Store away from children and misuse risks

Pharmacological Class of Tagrix

Tagrix 80 mg (Osimertinib) belongs to the pharmacological class of tyrosine kinase inhibitors (TKIs), specifically targeting the epidermal growth factor receptor (EGFR). It is classified as a third-generation EGFR-TKI, designed to block both activating EGFR mutations and the T790M resistance mutation in non-small cell lung cancer (NSCLC).

This class of drugs works by stopping cancer cell growth and division at the molecular level, making Tagrix a key player in targeted cancer therapy.

Manufactured by Beacon Pharmaceuticals Ltd.

Tagrix 80 mg is proudly manufactured by Beacon Pharmaceuticals Ltd., one of Bangladesh’s leading pharmaceutical exporters. Beacon is known for producing high-quality, affordable oncology medicines that meet international standards. The company follows strict GMP guidelines and exports its products to over 100 countries worldwide. Patients and healthcare professionals trust Beacon for its innovation, accessibility, and global reputation.

What sets Incepta apart?

• Exports affordable cancer medicines to 100+ countries.
• Follows strict WHO-GMP and global quality standards.
• Develops advanced generics like Tagrix (osimertinib).
• Makes targeted therapies more affordable.
• Trusted by doctors and patients worldwide.

Tagrix Price and Online Buying Guide

One of the key advantages of Tagrix 80 mg is its affordability compared to the original brand Tagrisso by AstraZeneca. 

Current Price:

• $310.00 USD per box (Beacon Pharmaceuticals Ltd.)
• Includes pharmacist support and verified product details

How to Buy Online:

• Visit unitpharmacy.com 
• Add to cart → Checkout
• Choose shipping and payment options
• Prescription verified → Order shipped globally

Why Choose Us:

• 100% genuine Osimertinib
• Affordable Osimertinib alternative
• Trusted by patients worldwide
• Safe, fast, and discreet delivery

If you’re searching for “Tagrix near me” or “buy online medicine Tagrix”, Unit Pharmacy is your trusted source. We provide affordable Tagrix, shipped globally, with complete patient support.

Tagrix Other Names and Alternatives

• Generic Name: Osimertinib
• Brand Name: Tagrix (Beacon Pharma)
• Global Brand: Tagrisso (AstraZeneca)

If you’re comparing prices or options, remember that Tagrix 80 mg medicine offers the same active ingredient as Tagrisso at a much lower cost. Other generic versions may also exist, but Tagrix by Beacon is one of the most trusted and widely used.

Supplied by Unit Pharmacy: Trusted Worldwide

At Unit Pharmacy, we specialize in oncology medicines, genuine products, and ensure access to affordable life-saving drugs like Tagrix 80 mg.

Why Buy Tagrix from Unit Pharmacy?

• Original product from Beacon Pharmaceuticals Ltd.
• Competitive cost
• Safe and secure checkout
• Fast worldwide delivery
• Trusted by customers worldwide.

Whether you’re looking to buy Tagrix online or searching for affordable Osimertinib, we are here to help.

Storage Instructions

• Store Tagrix 80 mg tablets below 30°C
• Keep out of reach of children
• Protect from direct light and moisture

Conclusion: Why Choose Tagrix 80 mg?

Tagrix 80 mg is a clinically trusted, patient-friendly, and cost-effective choice for the treatment of NSCLC with EGFR mutations. With the active ingredient Osimertinib, it offers targeted action, improved survival rates, and fewer side effects compared to older therapies. Its affordable price, especially from Unit Pharmacy, ensures accessibility for patients globally.

If you’re ready to begin or continue your cancer treatment journey, you can buy online medicine Tagrix 80 mg today with confidence.